Equities Analysts Offer Predictions for Kamada Q4 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright dropped their Q4 2024 earnings estimates for Kamada in a report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.05 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.26 per share. HC Wainwright also issued estimates for Kamada’s FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $42.47 million during the quarter, compared to analyst estimates of $39.70 million. Kamada had a return on equity of 6.36% and a net margin of 9.92%.

Separately, StockNews.com downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Stock Performance

NASDAQ:KMDA opened at $5.85 on Friday. The stock has a 50-day simple moving average of $5.47 and a two-hundred day simple moving average of $5.46. The firm has a market capitalization of $336.26 million, a PE ratio of 20.89 and a beta of 1.05. Kamada has a 52-week low of $4.60 and a 52-week high of $6.53.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Plato Investment Management Ltd purchased a new position in shares of Kamada in the third quarter valued at about $117,000. Vanguard Group Inc. grew its position in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares in the last quarter. Finally, Y.D. More Investments Ltd raised its stake in Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 690,842 shares during the period. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.